🔎 Trials Near Me

Dachaigh › Ailseachadh nan Sgamhan › Montana › Billings

Sgrùdaidhean clionaigeach Ailseachadh nan Sgamhan ann an Billings, MT

Tha 13 sgrùdaidhean airson Ailseachadh nan Sgamhan a’ lorg phàirtichean aig làraichean ann agus timcheall air Billings (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.

Teacsa sgrùdaidh oifigeil (Beurla)

A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

A’ fastadhÌre 3
  • Billings Clinic Cancer Center, Billings
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT04267848

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
  • Billings Clinic Cancer Center, Billings
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

A’ fastadhÌre 3
  • Billings Clinic Cancer Center, Billings
Aoisean 70 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

A’ fastadhÌre 3
  • Billings Clinic Cancer Center, Billings
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT04181060

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

A’ fastadhÌre 3
  • Billings Clinic Cancer Center, Billings
  • Saint Vincent Frontier Cancer Center, Billings
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06498635

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

A’ fastadhÌre 3
  • St. Vincent Frontier Cancer Center, Billings
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT06881784

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

A’ fastadhÌre 3
  • SCL Health - Montana, Billings
  • SCL Health - Montana, Billings
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06758401

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

A’ fastadhÌre 3
  • Billings Clinic Cancer Center, Billings
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT05624996

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

A’ fastadhÌre 1/2
  • Intermountain Health - St. Vincent Frontier Cancer Center, Billings
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Ògmh 2026 · NCT06162221

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

A’ fastadhÌre 2
  • Billings Clinic Cancer Center, Billings
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Ògmh 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

A’ fastadhÌre 2
  • Billings Clinic Cancer Center, Billings
18 Minutes · Gach gnè · Air ùrachadh 5 Cèit 2026 · NCT06031688

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

A’ fastadhSgrùdadh amharc
  • Massive Bio SYNERGY-AI site, Billings
Gach aois · Gach gnè · Air ùrachadh 28 Dàmh 2025 · NCT03452774

Sgrùdaidhean Ailseachadh nan Sgamhan ann am bailtean eile

Sgrùdaidhean eile ann an Billings

Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.